{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T20:36:16Z","timestamp":1774730176133,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.vaccine.2007.11.095","type":"journal-article","created":{"date-parts":[[2008,1,17]],"date-time":"2008-01-17T12:39:57Z","timestamp":1200573597000},"page":"933-946","source":"Crossref","is-referenced-by-count":30,"title":["Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination"],"prefix":"10.1016","volume":"26","author":[{"given":"Douglas W.","family":"Grosenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aklile","family":"Berhanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis K.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana L.","family":"Kirkwood-Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthakumar","family":"Tyavanagimatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin F.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis E.","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2007.11.095_bib1","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1128\/JVI.70.10.7103-7107.1996","article-title":"Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo","volume":"70","author":"Sharma","year":"1996","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.11.095_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/1043-4666(92)90068-3","article-title":"Biological effects of recombinant vaccinia virus-expressed interleukin 4","volume":"4","author":"Andrew","year":"1992","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.vaccine.2007.11.095_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.spid.2004.09.001","article-title":"Monkeypox: a review of the history and emergence in the Western hemisphere","volume":"15","author":"Ligon","year":"2004","journal-title":"Semin Pediatr Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2007.11.095_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0014-5793(01)03144-1","article-title":"Human monkeypox and smallpox viruses: genomic comparison","volume":"509","author":"Shchelkunov","year":"2001","journal-title":"FEBS Lett"},{"issue":"4","key":"10.1016\/j.vaccine.2007.11.095_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/infdis\/122.4.303","article-title":"Complications of smallpox vaccination, 1968: results of ten statewide surveys","volume":"122","author":"Lane","year":"1970","journal-title":"J Infect Dis"},{"issue":"5013","key":"10.1016\/j.vaccine.2007.11.095_bib6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1126\/science.2047875","article-title":"Vaccinia virus: a tool for research and vaccine development","volume":"252","author":"Moss","year":"1991","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2007.11.095_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-50-1-89","article-title":"Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia","volume":"50","author":"Payne","year":"1980","journal-title":"J Gen Virol"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2007.11.095_bib8","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J Gen Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2007.11.095_bib9","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1128\/JVI.65.11.5910-5920.1991","article-title":"Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein","volume":"65","author":"Blasco","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.11.095_bib10","first-page":"158","article-title":"Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R","author":"Gurt","year":"2005","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.vaccine.2007.11.095_bib11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/JVI.70.1.272-281.1996","article-title":"Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus","volume":"70","author":"McIntosh","year":"1996","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2007.11.095_bib12","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1128\/JVI.67.8.4732-4741.1993","article-title":"Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination","volume":"67","author":"Wolffe","year":"1993","journal-title":"J Virol"},{"issue":"20","key":"10.1016\/j.vaccine.2007.11.095_bib13","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.11.095_bib14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.00879-06","article-title":"Efficacy of delayed treatment of ST-246 given orally against systemic orthopoxvirus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2007.11.095_bib15","series-title":"Current protocols in molecular biology","first-page":"16.16.1","article-title":"Preparation of cell cultures and vaccinia virus stocks","author":"Earl","year":"1998"},{"key":"10.1016\/j.vaccine.2007.11.095_bib16","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hygeine"},{"issue":"7","key":"10.1016\/j.vaccine.2007.11.095_bib17","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/JVI.76.7.3329-3337.2002","article-title":"Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope","volume":"76","author":"Harrington","year":"2002","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2007.11.095_bib18","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1128\/JCM.41.7.3154-3157.2003","article-title":"Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine","volume":"41","author":"Newman","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.11.095_bib19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4269\/ajtmh.2007.76.768","article-title":"Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection","volume":"76","author":"Sbrana","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"18","key":"10.1016\/j.vaccine.2007.11.095_bib20","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J Virol"},{"issue":"13","key":"10.1016\/j.vaccine.2007.11.095_bib21","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.vaccine.2007.11.095_bib22","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: long-term B cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.11.095_bib23","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/JVI.70.4.2627-2631.1996","article-title":"Human cytotoxic T-cell memory: long-lived responses to vaccinia virus","volume":"70","author":"Demkowicz","year":"1996","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2007.11.095_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.vaccine.2007.11.095_bib25","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1128\/JVI.78.13.7052-7060.2004","article-title":"Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses","volume":"78","author":"Snyder","year":"2004","journal-title":"J Virol"},{"issue":"13","key":"10.1016\/j.vaccine.2007.11.095_bib26","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1128\/JVI.00427-06","article-title":"Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB\/c mice","volume":"80","author":"Tscharke","year":"2006","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.11.095_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1084\/jem.20041912","article-title":"Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines","volume":"201","author":"Tscharke","year":"2005","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2007.11.095_bib28","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.174.4.2212","article-title":"Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles","volume":"174","author":"Mathew","year":"2005","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.11.095_bib29","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"Kemper","year":"2002","journal-title":"Eff Clin Pract"},{"issue":"1","key":"10.1016\/j.vaccine.2007.11.095_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"issue":"6979","key":"10.1016\/j.vaccine.2007.11.095_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2007.11.095_bib32","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.vaccine.2005.03.029","article-title":"Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge","author":"Empig","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2007.11.095_bib33","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1073\/pnas.0406671102","article-title":"Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8","volume":"102","author":"Kidokoro","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.vaccine.2007.11.095_bib34","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified vaccinia Ankara: potential as an alternative smallpox vaccine","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2007.11.095_bib35","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","article-title":"An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection","volume":"79","author":"Morikawa","year":"2005","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2007.11.095_bib36","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.11.095_bib37","first-page":"2065","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","author":"Vollmar","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2007.11.095_bib38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"issue":"25\/26","key":"10.1016\/j.vaccine.2007.11.095_bib39","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2007.11.095_bib40","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.11.095_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host","volume":"345","author":"Fang","year":"2006","journal-title":"Virology"},{"issue":"19","key":"10.1016\/j.vaccine.2007.11.095_bib42","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2007.11.095_bib43","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.addr.2005.01.015","article-title":"Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism","volume":"57","author":"Wilson","year":"2005","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07014375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07014375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T22:09:41Z","timestamp":1588284581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07014375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0264410X07014375"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.11.095","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}